RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $2.36 billion. The enterprise value is $2.24 billion.
| Market Cap | 2.36B |
| Enterprise Value | 2.24B |
Important Dates
The last earnings date was Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 38.98 million shares outstanding. The number of shares has increased by 16.46% in one year.
| Shares Outstanding | 38.98M |
| Shares Change (YoY) | +16.46% |
| Shares Change (QoQ) | +2.40% |
| Owned by Insiders (%) | 5.08% |
| Owned by Institutions (%) | 83.52% |
| Float | 32.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 172.41 |
| PS Ratio | 23.38 |
| Forward PS | 16.37 |
| PB Ratio | 14.42 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 22.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.20, with a Debt / Equity ratio of 0.02.
| Current Ratio | 9.20 |
| Quick Ratio | 8.05 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -23.59 |
Financial Efficiency
Return on equity (ROE) is -27.70% and return on invested capital (ROIC) is -28.63%.
| Return on Equity (ROE) | -27.70% |
| Return on Assets (ROA) | -24.00% |
| Return on Capital (ROIC) | -28.63% |
| Revenue Per Employee | $270,324 |
| Profits Per Employee | -$118,973 |
| Employee Count | 374 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.01 |
Taxes
In the past 12 months, RxSight has paid $29,000 in taxes.
| Income Tax | 29,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +153.13% in the last 52 weeks. The beta is 1.20, so RxSight's price volatility has been higher than the market average.
| Beta (1Y) | 1.20 |
| 52-Week Price Change | +153.13% |
| 50-Day Moving Average | 53.97 |
| 200-Day Moving Average | 39.94 |
| Relative Strength Index (RSI) | 56.76 |
| Average Volume (30 Days) | 440,825 |
Short Selling Information
The latest short interest is 1.57 million, so 4.04% of the outstanding shares have been sold short.
| Short Interest | 1.57M |
| Short Previous Month | 1.47M |
| Short % of Shares Out | 4.04% |
| Short % of Float | 4.90% |
| Short Ratio (days to cover) | 4.77 |
Income Statement
In the last 12 months, RxSight had revenue of $101.10 million and -$44.50 million in losses. Loss per share was -$1.25.
| Revenue | 101.10M |
| Gross Profit | 64.09M |
| Operating Income | -47.66M |
| Pretax Income | -44.47M |
| Net Income | -44.50M |
| EBITDA | -38.28M |
| EBIT | -42.66M |
| Loss Per Share | -$1.25 |
Balance Sheet
The company has $126.07 million in cash and $2.52 million in debt, giving a net cash position of $123.54 million or $3.17 per share.
| Cash & Cash Equivalents | 126.07M |
| Total Debt | 2.52M |
| Net Cash | 123.54M |
| Net Cash Per Share | $3.17 |
| Equity / Book Value | 163.93M |
| Book Value Per Share | 4.21 |
| Working Capital | 150.23M |
Cash Flow
In the last 12 months, operating cash flow was -$33.14 million and capital expenditures -$6.03 million, giving a free cash flow of -$39.17 million.
| Operating Cash Flow | -33.14M |
| Capital Expenditures | -6.03M |
| Free Cash Flow | -39.17M |
| FCF Per Share | -$1.06 |
Margins
Gross margin is 63.39%, with operating and profit margins of -47.14% and -44.01%.
| Gross Margin | 63.39% |
| Operating Margin | -47.14% |
| Pretax Margin | -43.98% |
| Profit Margin | -44.01% |
| EBITDA Margin | -37.86% |
| EBIT Margin | -42.19% |
| FCF Margin | -38.75% |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.46% |
| Shareholder Yield | -16.46% |
| Earnings Yield | -1.88% |
| FCF Yield | -1.66% |
Analyst Forecast
The average price target for RxSight is $64.71, which is 6.69% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $64.71 |
| Price Target Difference | 6.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 26.49% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 69.89 and a Piotroski F-Score of 4.
| Altman Z-Score | 69.89 |
| Piotroski F-Score | 4 |